Cytomegalovirus colitis complicating inflammatory bowel disease.

Area of Science:

• Gastroenterology
• Infectious Diseases
• Immunology

Background:

• Inflammatory bowel disease (IBD) patients with acute severe colitis flares are often evaluated for concurrent cytomegalovirus (CMV) infection.
• Immunosuppression in IBD patients increases the risk of active CMV infection and disease.
• Accurate diagnosis of CMV is crucial for appropriate management.

Purpose of the Study:

• To review the diagnostic methods for CMV infection in IBD patients with acute severe colitis.
• To determine the prevalence of CMV infection in this patient population.
• To evaluate the efficacy of antiviral therapy for CMV-associated colitis in IBD.

Main Methods:

• Review of diagnostic techniques including endoscopy, histology, serology, viral culture, antigen testing, and DNA testing.
• Focus on immunohistochemistry (IHC) using monoclonal antibodies against CMV immediate early antigen as the gold standard.
• Analysis of prevalence data and treatment outcomes from existing literature.

Main Results:

• The prevalence of CMV infection in acute severe colitis ranges from 21-34%, and 33-36% in steroid-refractory cases.
• Immunohistochemistry (IHC) on colon biopsies is the gold standard for diagnosing CMV infection.
• Colitis remission rates after antiviral therapy are high (67-100%), but CMV presence alone doesn't always indicate steroid resistance or necessitate treatment.

Conclusions:

• Cytomegalovirus (CMV) infection is a significant consideration in hospitalized inflammatory bowel disease (IBD) patients experiencing acute severe colitis flares.
• While immunohistochemistry (IHC) is the gold standard for diagnosis, not all CMV infections require antiviral therapy, as steroid resistance is not always linked to viral presence.
• Antiviral treatment demonstrates high remission rates in CMV-positive IBD patients, underscoring the importance of accurate diagnosis and tailored management strategies.